|
Palo Alto, CA, June 9, 2006 — Telik, Inc. (Nasdaq: TELK) announced that company management will provide corporate overviews at the following investment conferences:
- Monday, June 12, 2006, 2:30 pm EDT (11:30 am PDT): Pacific Growth Equities Life Sciences Growth Conference, San Francisco
- Wednesday, June 14, 8:30 am EDT (5:30 am PDT): Needham & Company, LLC Fifth Annual Biotechnology and Medical Technology Conference, New York City
- Wednesday, June 21, 2006, 10:15 am EDT (7:15 am PDT): Wachovia Securities 16 th Annual Nantucket Equity Conference, Nantucket MA
Live and archived webcasts of these presentations will be available via the Telik website, www.telik.com.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA® (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA™ (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
